(2005) (2 R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro [1, 2, 4] triazolo [4, 3-a] pyrazin-7 (8 H)-yl]-1-(2, 4, 5-trifluorophenyl) butan-2-amine: a Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
While the evidence is still emerging, the possibility merits serious investigation, particularly if these agents are viewed not solely as metabolic drugs but as broader healthspan interventions with effects that extend to the brain, inflammation, and systemic physiology
We outline the key provisions that pharmacists secured in these bills for advocates and pharmacists to use as a model in their states
Adjustments in diet and hydration often help mitigate these effects
doi: 10.1056/NEJMoa1607141 Rubino D, Abrahamsson N, Davies M, et al